MX2022008745A - Anticuerpos anti-nkp30 y metodos de uso. - Google Patents

Anticuerpos anti-nkp30 y metodos de uso.

Info

Publication number
MX2022008745A
MX2022008745A MX2022008745A MX2022008745A MX2022008745A MX 2022008745 A MX2022008745 A MX 2022008745A MX 2022008745 A MX2022008745 A MX 2022008745A MX 2022008745 A MX2022008745 A MX 2022008745A MX 2022008745 A MX2022008745 A MX 2022008745A
Authority
MX
Mexico
Prior art keywords
antibodies
nkp30
methods
antigen
nkp30 antibodies
Prior art date
Application number
MX2022008745A
Other languages
English (en)
Inventor
Tong Zhang
Liu Xue
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of MX2022008745A publication Critical patent/MX2022008745A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona anticuerpos y fragmentos de unión a antígeno de los mismos que se unen a la NKp30 humana, anticuerpos multiespecíficos que reconocen la NKp30 como un antígeno y al menos otro antígeno, una composición farmacéutica que comprende anticuerpos NKp30, y el uso del anticuerpo, el anticuerpo multiespecífico o la composición para el tratamiento de una enfermedad, como el cáncer.
MX2022008745A 2020-01-17 2021-01-15 Anticuerpos anti-nkp30 y metodos de uso. MX2022008745A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020072733 2020-01-17
PCT/CN2021/072191 WO2021143858A1 (en) 2020-01-17 2021-01-15 ANTI-NKp30 ANTIBODIES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
MX2022008745A true MX2022008745A (es) 2022-07-27

Family

ID=76863642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008745A MX2022008745A (es) 2020-01-17 2021-01-15 Anticuerpos anti-nkp30 y metodos de uso.

Country Status (11)

Country Link
EP (1) EP4090684A4 (es)
JP (1) JP2023510211A (es)
KR (1) KR20220151164A (es)
CN (1) CN115397854A (es)
AU (1) AU2021207165A1 (es)
BR (1) BR112022013977A2 (es)
CA (1) CA3164182A1 (es)
IL (1) IL294714A (es)
MX (1) MX2022008745A (es)
TW (1) TW202140556A (es)
WO (1) WO2021143858A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080063717A1 (en) * 2002-12-23 2008-03-13 Innate Pharma, S.A.S. Pharmaceutical Compositions Having an Effect on the Proliferation of Nk Cells and a Method Using the Same
ES2629440T5 (es) * 2007-10-04 2020-11-20 Zymogenetics Inc zB7H6 miembro de la familia B7 y composiciones y métodos relacionados
MX2012006443A (es) * 2009-12-09 2012-06-28 Inst Nat Sante Rech Med Anticuerpos monoclonales que se enlazan a b7h6 y usos de los mismos.
CN101985476B (zh) * 2010-10-29 2012-11-21 中国科学技术大学 抗人NKp30单克隆抗体的制备、鉴定及应用
WO2013033626A2 (en) * 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
JP7012645B2 (ja) * 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
IL269203B1 (en) * 2017-03-13 2024-05-01 Poseida Therapeutics Inc Preparations and methods for the selective elimination and replacement of hematopoietic stem cells
CA3099308A1 (en) * 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells

Also Published As

Publication number Publication date
CN115397854A (zh) 2022-11-25
IL294714A (en) 2022-09-01
JP2023510211A (ja) 2023-03-13
EP4090684A4 (en) 2024-01-31
EP4090684A1 (en) 2022-11-23
CA3164182A1 (en) 2021-07-22
WO2021143858A1 (en) 2021-07-22
KR20220151164A (ko) 2022-11-14
BR112022013977A2 (pt) 2023-03-14
AU2021207165A1 (en) 2022-07-21
TW202140556A (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
CR20200466A (es) Agentes anticuerpos anti-cd25
PH12017502358A1 (en) Factor xi antibodies and methods of use
MY194997A (en) Anti-ccr7 antibody drug conjugates
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
MX2020008736A (es) Formulaciones de anticuerpos b7-h4.
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2020012567A (es) Anticuerpos anti-ox40 y metodos de uso.
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2020008122A (es) Anticuerpos anti-pd-1.
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2021004226A (es) Terapia combinada contra el cáncer.
ZA202008095B (en) Humanized antibodies against psma
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
CO2023017609A2 (es) Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso
PH12020551453A1 (en) Anti-cd25 for tumour specific cell depletion
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.